Chemiesynth Vapi Limited has announced the allotment of 1 crore unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) worth ₹10 crore through private placement. The company's Board of Directors approved the allotment at its meeting held on October 28, 2026.

According to the company's regulatory filing submitted to BSE Limited, the allotment was completed under the first tranche after receiving approval from the company's members and the subscription money. Each preference share has a face value of ₹10 and has been issued at ₹10, which is at par with the face value, as stated in the company's disclosure.

The total issue size amounts to ₹10 crore. The securities are unlisted, meaning they will not be listed for trading on a stock exchange under the terms disclosed in this announcement.

The preference shares carry a 5% cumulative annual dividend and have a maturity period of seven years from the date of allotment. The allotment date is October 28, 2026, while the stated maturity date is October 28, 2033, subject to the terms of issue and applicable law.

The company has also disclosed that the preference shares are unsecured and do not carry any charge over its assets. The instrument provides preferential rights compared with equity shares concerning dividend payments and repayment in the event of winding up or repayment of capital.

This corporate announcement is important for investors tracking Chemiesynth Vapi Limited, its capital structure and its financing activities. However, the allotment of preference shares should be understood separately from the company's ordinary equity shares and its share-price movements.

Chemiesynth Vapi Limited Announces ₹10 Crore NCRPS Allotment

Chemiesynth Vapi Limited informed BSE Limited about the board-approved allotment of non-convertible redeemable preference shares under the first tranche of a private placement.

The company made the disclosure on October 28, 2026, under Regulation 30 of the Securities and Exchange Board of India's Listing Obligations and Disclosure Requirements Regulations, 2015.

The board considered and approved the allotment after the company received the necessary approval from its members and the subscription money. The company also authorised the required statutory filings, corporate actions and other consequential actions connected with the allotment.

The main details of the issue are as follows:

The announcement provides information about the size, structure and principal terms of the preference share allotment. It does not, by itself, provide a complete explanation of how the proceeds will be used or the expected financial impact on the company's business.

Investors should therefore distinguish between the confirmed allotment details and any assumptions about the company's future financial performance.

What Are Non-Convertible Cumulative Redeemable Preference Shares?

To understand the announcement, it is important to understand the meaning of Non-Convertible Cumulative Redeemable Preference Shares, commonly known as NCRPS.

These securities have characteristics that differ from ordinary equity shares.

Non-convertible means that the securities are not intended to be converted into ordinary equity shares under the terms described for the instrument. Unlike convertible securities, which may provide a route to equity ownership, non-convertible preference shares remain preference share instruments unless their terms or applicable legal provisions provide otherwise.

Cumulative refers to the treatment of dividends under the instrument. A cumulative preference share carries a right to accumulate unpaid dividends in accordance with its terms. The exact conditions governing the accumulation and payment of dividends are determined by the issue terms and applicable law.

Redeemable means that the preference shares are intended to be repaid or redeemed according to the specified terms. In this case, Chemiesynth Vapi Limited has stated a seven-year maturity period, with the stated maturity date falling on October 28, 2033, subject to the terms of issue and applicable law.

Preference shares have preferential rights compared with ordinary equity shares for specified matters. In this issue, the company has disclosed preferential rights concerning dividend payments and repayment in the event of winding up or repayment of capital.

These characteristics make NCRPS different from ordinary equity shares. Equity shareholders generally participate in the company's residual profits and capital value, while preference shareholders have rights defined by the terms of their preference shares.

However, preference shares are not identical to bank deposits or guaranteed-return products. Their rights, dividend provisions, redemption conditions and associated risks depend on the issue documents and the company's financial position.

Issue Price and Total Value of the Preference Shares

Chemiesynth Vapi Limited allotted 1 crore preference shares at ₹10 per share.

The calculation of the total issue size is straightforward:

• Number of preference shares: 1,00,00,000

• Issue price per share: ₹10

• Total issue value: ₹10,00,00,000

• Total issue size: ₹10 crore

The issue price is equal to the face value of ₹10 per share. Therefore, the preference shares have been issued at par, as stated in the company's filing.

The company has described the allotment as a private placement under the first tranche. Private placement refers to the issue of securities to selected investors under the applicable legal framework rather than an offer made to the general public through a public issue.

The announcement confirms the total number of securities allotted and the aggregate value of the issue. It does not identify the individual allottees or provide a complete breakdown of their respective holdings in the supplied details.

The issue size should also not automatically be interpreted as an increase in the company's ordinary equity share capital. Preference shares are a distinct class of securities, and their accounting and capital-structure treatment depends on the applicable requirements and the terms of issue.

For investors studying the company's financial position, the key point is that Chemiesynth Vapi Limited has completed a ₹10 crore preference share allotment under the first tranche of the private placement.

Understanding the 5% Cumulative Annual Dividend

One of the most important features of the issue is the 5% cumulative annual dividend.

The company has disclosed that the preference shares carry a dividend rate of 5% per annum, payable according to the terms of issue and applicable law.

Based on the stated issue price of ₹10 per preference share, a 5% annual dividend corresponds to ₹0.50 per share for a full year, assuming the dividend is calculated on the issue price and the relevant conditions for payment are satisfied.

For the entire allotment of 1 crore preference shares, the illustrative annual dividend amount would be:

This calculation illustrates the amount associated with the stated dividend rate. It should not be treated as confirmation that ₹50 lakh will necessarily be paid in cash every year, because actual payment remains subject to the terms of issue and applicable law.

The cumulative feature means that the treatment of unpaid dividends is governed by the relevant conditions of the instrument. Investors should read the issue documents carefully to understand when dividends become payable, how unpaid dividends accumulate and what conditions apply to payment.

The announcement does not provide a detailed payment calendar or specify every condition governing the payment of dividends. Those matters should not be assumed beyond what is stated in the official terms.

It is also important to distinguish a dividend rate from a guaranteed return. The 5% figure is the stated annual dividend rate for the preference shares, but the actual rights and payment obligations must be assessed under the instrument's terms and applicable legal provisions.

Seven-Year Maturity Period: From 2026 to 2033

Chemiesynth Vapi Limited has disclosed a seven-year tenure for the preference shares.

The date of allotment is October 28, 2026, and the stated maturity date is October 28, 2033.

The seven-year maturity period provides a defined time frame for the instrument. Under the terms disclosed, redemption is expected at the end of the stated tenure, subject to applicable law and the terms of issue.

Redemption refers to the process through which the company repays the preference share capital according to the instrument's conditions. The company has stated that redemption will take place at the expiry of seven years from allotment, subject to applicable law and the issue terms.

The announcement also refers to a company call option and an investor put option that may be exercisable after two years. These options are subject to the terms of issue and a 30-day notice requirement.

The availability of these options may allow for redemption-related action before the stated maturity date, depending on the conditions specified in the issue documents. However, the announcement does not provide the full wording of the call and put provisions or every condition that would govern their exercise.

Investors should therefore not assume that an early redemption will occur automatically after two years. The relevant option must be assessed in accordance with the instrument's terms.

The distinction between the seven-year maturity and the potential early-exit provisions is important. The stated maturity date is October 28, 2033, while the options may be exercisable after two years only if the applicable conditions are satisfied.

What Are Company Call and Investor Put Options?

The company has stated that the preference shares may carry a company call option and an investor put option that could be exercisable after two years, subject to the issue terms and 30 days' notice.

These provisions are worth understanding because they may affect the timing of redemption.

A call option generally gives the issuer a right to redeem or repurchase a security under specified conditions. In this case, the company has disclosed that its call option may be exercisable after two years, subject to the issue terms.

A put option generally gives the investor a right to require the issuer to redeem or repurchase a security under specified conditions. Chemiesynth Vapi Limited has stated that an investor put option may also be exercisable after two years, subject to the issue terms.

The practical effect of these provisions depends on the detailed contractual terms, including eligibility, exercise conditions, notice requirements and the applicable redemption process.

The company has specified a 30-day notice requirement in connection with these options. However, the supplied announcement does not explain every procedural detail.

For this reason, investors should consult the full issue terms before drawing conclusions about the exact date, conditions or certainty of early redemption.

The options should also be considered separately from the seven-year maturity date. Their potential availability does not mean that all preference shares will necessarily be redeemed after two years.

NCRPS Are Unlisted Securities

Chemiesynth Vapi Limited has explicitly stated that the newly allotted preference shares are unlisted.

This means the NCRPS are not being listed for trading on a stock exchange under the disclosed issue terms. They should not be confused with the company's listed ordinary equity shares.

Unlisted securities may have different liquidity characteristics from listed securities. Investors generally cannot assume that an unlisted instrument can be sold through the regular exchange-trading mechanism used for listed shares.

The ability to transfer an unlisted security, if permitted, depends on applicable law and the relevant contractual terms. The supplied announcement does not set out a detailed transfer mechanism or confirm the existence of a secondary market for these preference shares.

This distinction is particularly important for investors who are familiar with listed equity shares. The fact that Chemiesynth Vapi Limited has a BSE-listed equity security does not mean that every security issued by the company is also listed.

The announcement specifically identifies the NCRPS as unlisted. Investors should therefore assess their liquidity expectations based on the instrument's terms rather than assuming that the preference shares can be traded on BSE.

The Preference Shares Are Unsecured

Another significant detail in the announcement is that the preference shares are unsecured.

The company has stated that the NCRPS do not carry any charge over its assets.

A secured instrument generally benefits from specified security over assets, subject to the terms of the security arrangement. An unsecured instrument does not carry such a charge over company assets under its disclosed terms.

For investors, this is an important risk consideration. The preference shares provide specified preferential rights compared with ordinary equity shares, but they do not have the asset charge described in the filing as absent.

The preference rights concerning dividend payments and repayment of capital should not be confused with a guarantee that investors will receive every amount on a particular date irrespective of the company's financial position.

The terms of the instrument, applicable law and the company's ability to meet its obligations remain relevant to the assessment.

The announcement does not provide a credit rating for the NCRPS or a separate assessment of the company's capacity to meet future dividend and redemption obligations. Therefore, no conclusion about the instrument's credit quality should be drawn solely from the allotment announcement.

Investors assessing the NCRPS should consider the company's financial position, its other liabilities, the instrument's contractual rights and the risks associated with an unsecured investment.

Preferential Rights Compared With Equity Shares

The preference shares carry preferential rights concerning dividend payments and repayment in the event of winding up or repayment of capital, according to the company's disclosure.

These rights distinguish preference shares from ordinary equity shares.

Ordinary equity shareholders generally hold residual ownership interests in a company. Their returns can depend on dividends declared by the company and changes in the market value of their shares.

Preference shareholders have rights determined by the terms of their preference shares. In this case, the company has stated that the NCRPS rank preferentially to equity shares for the specified dividend and capital-repayment matters.

However, the announcement does not provide a complete ranking of these securities against every other category of creditor or liability. It would therefore be inappropriate to infer a full recovery priority structure beyond the preference rights expressly disclosed.

The NCRPS are also non-convertible, so investors should not assume that holding them automatically provides a route to ownership through ordinary equity shares.

The main distinction is that the new instrument has its own dividend rate, maturity period, redemption terms and preferential rights. It is separate from the company's listed equity shares.

Why Has Chemiesynth Vapi Limited Issued NCRPS?

The supplied announcement confirms the allotment but does not specify the intended use of the ₹10 crore proceeds.

As a result, it would not be appropriate to state that the funds will be used for a particular purpose, such as working capital, capital expenditure, debt repayment, business expansion or acquisitions, unless the company provides further information.

The confirmed information is that the company issued the securities through private placement under the first tranche, following approval from its members and receipt of subscription money.

The company also authorised statutory filings and other actions needed to complete the allotment process.

To understand the broader financial impact of the transaction, investors would need to review any additional disclosures concerning the use of funds, the identity of the investors, the terms of the issue and the company's financial position.

The allotment may affect the company's capital structure and future financing obligations, but the precise impact should be assessed using the complete issue documents and relevant financial statements.

A careful reading of the disclosure helps distinguish between the confirmed transaction details and any assumptions about management's financing strategy.

What Does the Allotment Mean for Chemiesynth Vapi Shareholders?

The announcement concerns the allotment of preference shares rather than a stock split, bonus issue or fresh allotment of ordinary equity shares.

The newly issued securities are non-convertible preference shares. They carry a stated 5% cumulative annual dividend and a seven-year maturity period, subject to the issue terms and applicable law.

For existing equity shareholders, the transaction is relevant because it adds another class of securities to the company's capital structure. The rights associated with those securities differ from the rights of ordinary equity shareholders.

However, the supplied announcement does not provide enough information to determine the transaction's precise effect on earnings per share, valuation, debt ratios or future profitability.

The issue price and total value of the NCRPS also should not be used on their own to estimate the company's equity value or market capitalisation.

Investors following Chemiesynth Vapi share price movements should therefore avoid treating the ₹10 crore preference share allotment as a direct indication of future share-price performance.

The market price of listed equity shares may be affected by a range of factors, including the company's financial results, business outlook, valuation, liquidity and overall market conditions.

The preference share allotment is a disclosed financing-related corporate action. Its long-term significance will depend on the full terms of the securities and the company's ability to meet its obligations.

Key Risks and Points Investors Should Consider

Before assessing the significance of the NCRPS allotment, investors should keep several points in mind.

First, the securities are unlisted. The announcement does not establish that a regular exchange-trading market will be available for the preference shares. Investors should examine the applicable transfer provisions and liquidity conditions.

Second, the securities are unsecured. The company has stated that the NCRPS do not carry any charge over its assets. This is relevant when assessing the instrument's risk characteristics.

Third, the dividend is subject to the issue terms and applicable law. Although the stated annual dividend rate is 5% cumulative, investors should review the full terms to understand the payment conditions and treatment of unpaid dividends.

Fourth, redemption is subject to the stated terms. The maturity date is October 28, 2033, and the company has disclosed potential call and put options after two years. The options are subject to the issue terms and a 30-day notice requirement.

Fifth, the announcement does not provide a credit rating or a detailed assessment of redemption capacity. Investors should not assume that the stated dividend and maturity terms eliminate the risk associated with the issuer's financial position.

Sixth, the use of proceeds is not specified in the supplied disclosure. Investors should avoid assuming that the ₹10 crore will be used for a particular business purpose without additional information from the company.

These points do not determine whether the instrument is suitable for a particular investor. They highlight the areas that require examination before drawing conclusions about the securities.

Board Meeting Details and Regulatory Disclosure

Chemiesynth Vapi Limited held the relevant board meeting on Wednesday, October 28, 2026.

The meeting commenced at 11:30 AM and concluded at 12:00 noon, according to the company's filing.

The company submitted the disclosure to BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The filing was signed on behalf of Chemiesynth Vapi Limited by Pranali Dholabhai, Company Secretary and Compliance Officer, at Vapi, Gujarat.

The company also attached Annexure A, which provides the principal details of the preference share allotment, including the type of securities, issue method, total number of shares, face value, issue price, issue size, listing status, tenure, dividend rate, security status and redemption terms.

The regulatory disclosure gives shareholders and market participants information about the board-approved corporate action.

For a complete understanding of the transaction, the annexure should be read together with the underlying issue terms and any subsequent company announcements.

Frequently Asked Questions About Chemiesynth Vapi NCRPS Allotment

1. How many preference shares has Chemiesynth Vapi Limited allotted?

The company has allotted 1 crore Non-Convertible Cumulative Redeemable Preference Shares under the first tranche of a private placement.

2. What is the total value of the allotment?

The total issue size is ₹10 crore. Each preference share has a face value and issue price of ₹10.

3. What dividend rate do the NCRPS carry?

The securities carry a 5% cumulative annual dividend, payable according to the terms of issue and applicable law.

4. Are the preference shares listed on BSE?

No. The company has stated that the newly allotted NCRPS are unlisted. This should not be confused with the company's listed equity shares.

5. What is the maturity date of the preference shares?

The stated maturity date is October 28, 2033, seven years after the allotment date of October 28, 2026, subject to the terms of issue and applicable law.

6. Can the preference shares be redeemed before maturity?

The company has disclosed that a company call option and investor put option may be exercisable after two years. Their exercise is subject to the terms of issue and a 30-day notice requirement.

7. Are the preference shares secured against company assets?

No. The company has stated that the NCRPS are unsecured and do not carry any charge over its assets.

8. Will the preference shares convert into equity shares?

The securities are described as non-convertible preference shares. Investors should refer to the complete issue terms for the applicable rights and restrictions.

9. Has the company disclosed how it will use the ₹10 crore?

The supplied announcement does not specify the intended use of the proceeds. Any particular use should not be assumed without an additional disclosure.

10. Does the allotment guarantee a return of 5% every year?

The instrument carries a stated 5% cumulative annual dividend, subject to its terms and applicable law. Investors should not treat the stated rate as a guarantee independent of the instrument's conditions.

Final Takeaway

Chemiesynth Vapi Limited has completed the allotment of 1 crore unlisted Non-Convertible Cumulative Redeemable Preference Shares worth ₹10 crore under the first tranche of a private placement. The board approved the allotment on October 28, 2026, following member approval and receipt of the subscription money.

The preference shares have an issue price of ₹10 each and carry a 5% cumulative annual dividend. They have a stated seven-year maturity period, with an allotment date of October 28, 2026, and a maturity date of October 28, 2033, subject to the terms of issue and applicable law.

The company has also disclosed that the securities are unsecured and unlisted. A company call option and investor put option may be exercisable after two years, subject to the issue terms and a 30-day notice requirement.

For investors, the important point is to understand that these preference shares are different from ordinary equity shares. Their dividend, redemption, liquidity and preferential rights are governed by the specific terms of the instrument.

The allotment announcement confirms the transaction's size and principal features, but it does not specify the use of proceeds or provide a credit rating or detailed assessment of future redemption capacity.